An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension

This study has been terminated.

First Received: March 16, 2007 No Changes Posted

Sponsored by:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00449111

Purpose

Evaluate blood pressure after 6 weeks of treatment with COZAAR plus.

Condition	Intervention	Phase
Hypertension	Drug: MK0954, losartan potassium / Duration of Treatment - 12 weeks	Phase III

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment
Official Title:	An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Hydrochlorothiazide Losartan Losartan potassium Potassium chloride

U.S. FDA Resources

Further study details as provided by Merck:

Primary Outcome Measures:

Change of diastolic blood pressure after 6 weeks of treatment with cozaar plus

Estimated Enrollment:	138
Study Start Date:	January 2007

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patient treated with valsartan 80mg or irbesartan 150mg or vandesartan 8mg for at least 4 weeks prior to visit 1
Patient with systolic blood pressure between 140 to 159 mmhg and diastolic pressure between 90 to 99mmhg taken at visit 1

Exclusion Criteria:

History of angina pectoris that has not been stabilized in the past 6 weeks
History of clinically significant abnormal lab results or diseases
Myocardial infarction within the past 6 months
Stroke in the past 6 months

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00449111

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

No publications provided

Study ID Numbers:	2007_005
Study First Received:	March 16, 2007
Last Updated:	March 16, 2007
ClinicalTrials.gov Identifier:	NCT00449111 History of Changes
Health Authority:	Korea: Food and Drug Administration

Study placed in the following topic categories:

Angiotensin II Type 1 Receptor Blockers
Losartan
Essential Hypertension
Sodium Chloride Symporter Inhibitors
Diuretics
Vascular Diseases

Anti-Arrhythmia Agents
Cardiovascular Agents
Angiotensin II
Antihypertensive Agents
Hydrochlorothiazide
Hypertension

Additional relevant MeSH terms:

Losartan
Molecular Mechanisms of Pharmacological Action
Diuretics
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Vascular Diseases
Cardiovascular Agents
Antihypertensive Agents
Hydrochlorothiazide

Pharmacologic Actions
Angiotensin II Type 1 Receptor Blockers
Membrane Transport Modulators
Natriuretic Agents
Therapeutic Uses
Cardiovascular Diseases
Anti-Arrhythmia Agents
Hypertension

ClinicalTrials.gov processed this record on July 02, 2009